BIOCON.BO : Summary for BIOCON LTD. - Yahoo Finance

U.S. Markets closed

Biocon Limited (BIOCON.BO)


BSE - BSE Delayed Price. Currency in INR
Add to watchlist
1,124.90+19.65 (+1.78%)
At close: 3:57PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1,105.25
Open1,107.00
Bid0.00 x
Ask0.00 x
Day's Range1,092.00 - 1,133.00
52 Week Range454.30 - 1,133.00
Volume57,160
Avg. Volume71,501
Market Cap220.62B
BetaN/A
PE Ratio (TTM)25.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
    Zacks3 days ago

    Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

    Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

  • PR Newswire5 days ago

    U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

    HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta®  (pegfilgrastim), for filing through the 351(k) pathway.

  • Biocon Ltd. :532523-IN: Earnings Analysis: Q3, 2017 By the Numbers : February 1, 2017
    Capital Cube20 days ago

    Biocon Ltd. :532523-IN: Earnings Analysis: Q3, 2017 By the Numbers : February 1, 2017

    Categories: Yahoo Finance Get free summary analysis Biocon Ltd. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of INR 10225 million, Net Earnings of INR 1713 million. Gross margins widened from 35.56% to 41.86% compared to the same period last year, operating (EBITDA) margins now 25.53% from 17.31%. Earnings growth from operating ... Read more (Read more...)